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A B S T R A C T   
The COVID-19 pandemic has devastated individuals, families, and institutions throughout the world. Despite the 
breakneck speed of vaccine development, the human population remains at risk of further devastation. The 
decision to not become vaccinated, the protracted rollout of available vaccine, vaccine failure, mutational forms 
of the SARS virus, which may exhibit mounting resistance to our molecular strike at only one form of the viral 
family, and the rapid ability of the virus(es) to hitch a ride on our global transportation systems, means that we 
are will likely continue to confront an invisible, yet devastating foe. The enemy targets one of our human 
physiology’s most important and vulnerable life-preserving body tissues, our broncho-alveolar gas exchange 
apparatus. 
Notwithstanding the fear and the fury of this microbe’s potential to raise existential questions across the entire 
spectrum of human endeavor, the application of an early treatment intervention initiative may represent a 
crucial tool in our defensive strategy. This strategy is driven by evidence-based medical practice principles, those 
not likely to become antiquated, given the molecular diversity and mutational evolution of this very clever 
“world traveler”. 
☆ This paper, tables, figures and recommendations are meant to be followed in conjunction with the advice of a medical professional such as your Primary or 
Principal Care Provider. Although the recommendations are sound, there may be underlying reasons why a specific patient SHOULD NOT follow all of the rec-
ommendations. Please consult your Medical Provider for specific instructions and guidance. 
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1. Introduction 
Never before has the human family shared a more compelling and 
existential challenge from which to acknowledge our common plight, 
rather than our differences. Only through the establishment and mutual 
endorsement and enforcement of universal public health principles, 
collaborative research on a global scale, and universal preparedness to 
act decisively with early and strategically formulated interventions, can 
we hope to stay ahead of this most formidable foe [1,2]. 
Supported by long-established standards of care protocols, as well as 
randomized controlled trials aimed to either confirm or refute 
hypothesis-driven therapeutic questions on the efficacy of novel agents 
identified through innovations in discovery, we are on the brink of 
ushering in a literal Renaissance of modern medicine. The era’s over-
arching goal shall be to establish the most sophisticated attempt to date, 
utilizing discrete knowledge of human heterogeneity, for the identifi-
cation of effective treatments for even a single patient, the era of Pre-
cision CARE. Until then, we share herein a protocol for the early 
treatment of mild and moderate COVID-19, the purpose of which is to 
prevent the transition to severe disease. 
1.1. Omission of an early treatment strategic initiative fueled the hospital 
crisis 
The circumstances of the COVID-19 crisis created many formidably 
complex challenges in clinical trial design and execution. Nowhere has 
such complexity been more limiting than in the outpatient investigation 
of infected patients characterized as having mild to moderate disease, 
and who have been summarily sent home without education, coun-
seling, monitoring recommendations, nor with any treatment interven-
tion whatsoever. This in part is due to the overwhelming numbers of 
patients flooding our hospitals and point of care services, but also 
because our global healthcare system’s most precious asset, our ‘front- 
line-people’ (composed of physicians, nurses, nurse practitioners, physician 
assistants, and their support staff across the spectrum of emergency and acute 
care medical services), are tired and have been completely overwhelmed. 
Further, ‘our people’ have not been equipped with a systematic, 
educational, and corresponding out-patient multidisciplinary treatment 
strategy for mild and moderate COVID-19, with the specific aim of 
preventing the transition to severe disease, an achivement of monu-
mental significance for both those we serve, and for those with the un-
precedented fiduciary responsibilities who do the ‘serving’. 
Notwithstanding the preeminent importance of the expanding global 
vaccine initiative, and achieving the highly anticipated goal of herd 
immunity, in the interim, we are recognizing disseminated and 
dangerously expanding spikes in new cases of COVID-19. Mid-April 
2021 has the highest incident rates of the pandemic since the inception. 
This ominous observation, along with evidence of new cases emerging 
among vaccinated patients (as well as those who remain steadfast in 
their opposition to active immunization, at least via vaccination, a su-
perior method of actively acquired immunity when compared to 
developing COVID-19 via infection with the SARS-CoV-2 etiologic 
agent) provides the most compelling justification to date to offer COVID- 
19 patients specific treatment recommendations at the time of 
diagnostic confirmation, or as early as possible, and irrespective of 
symptom magnitude. 
Symptom severity has been demonstrated to poorly correlate (espe-
cially when considering individual patients, which is how we best pro-
vide CARE for them, individually, one at a time) with propensity to 
transition to severe disease. It is not uncommon to appreciate a 
mismatch between clinical semiology and the underlying histopatho-
logical burden of disease. This highly salient aspect of COVID-19 is not 
dissimilar to other conditions whereby the presence of a mild clinical 
disease phenotype does NOT militate against the simultaneous presence 
of occult disease activity. In fact, in a disease such as multiple sclerosis, a 
‘clinico-radiologic-paradox’, provides instructive principles which un-
derscore the powerful prognostic predictability for future severity of 
disability, contingent upon the dissemination and volumetric burden of 
central nervous system lesions, despite the absence of significant clinical 
correlation at the time of magnetic resonance imaging (MRI). Similarly, 
considerable and constitutively recalcitrant targeting, injury, and even 
obliteration of our bronchoalveolar gas-exchange apparatus, can pro-
gressively advance in a mildly affected COVID-19 patient (even in those 
completely asymptomatic), until a critical threshold of injury is excee-
ded such that the patient then exhibits the highly salient and most 
treatment refractory clinical characteristics, which are the cardinal 
hallmarks of severe COVID-19, the phase of this disease state which must 
be actively prevented in order to provide the best chance for optimizing 
recovery, limiting tissue and organ damage, thereby extending life and 
the quality of it. 
Our ‘front-line’ healthcare alliance desperately need a carefully 
assembled, and coherently codified, multidisciplinary, remission- 
exacting treatment strategy to prevent transition to severe disease. 
Such a tool could serve to literally decouple the vast out-patient popu-
lation of COVID-19 patients as the primary driving source for emergency 
and acute care service demands, which far exceeds the resources 
available, even within and across the most advanced, expansive, expe-
rienced and well-endowed healthcare systems and infrastructures in the 
world. Providing a pragmatic, evidence-based, and out-patient treat-
ment strategy, predicated upon established medical practice principles, 
and commensurate with the realistic objectives, and the much needed 
confidence to advance our capabilities from those of community ascer-
tainment, diagnostic confirmation, adoption of public health and home 
quarantine, to a bona fide disease-modifying strategy aimed at abol-
ishing COVID-19, and neutralizing its pathoetiologic agent, the SARS- 
CoV-2 virus. 
1.2. The telemedicine transformation: limitations and opportunities 
The near cessation of outpatient clinic medicine, and the trans-
formation to virtual telemedicine resulted in a critical disconnection 
between providers and patients, and the framework of systematic 
methods for translating clinical history and the performance of the 
directed examination into the corresponding formulation of diagnostic 
and treatment plans. Alternately, the rapid availability and adoption of 
the telemedicine platform did allow us to use a convenience sample of 
consecutive patients seeking our help with COVID-19 management. 
Disseminating information about their experience to family, friends, and 
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colleagues has led to a nearly geometric application of our current 
treatment protocol, outlined in this paper, to COVID-19 patients 
throughout the country and globally. 
Our willingness to provide counsel and specific treatment recom-
mendations, based upon established and evidence-based, medical 
practice principles, has compelled us to share information germane to 
already established standards of care. The number of lives potentially 
saved with this protocol, as well as those protected from the potential of 
residual deficits we now recognize to be plaguing many patients, “the 
long-haulers syndrome”, grows as we target those who were designated as 
having mild to moderate disease or even asymptomatic individuals. 
2. Outcome observations of early treatment intervention 
At the time of the completion of this manuscript for submission, the 
lead author treated more than 125 patients with confirmed COVID-19 
following the protocol described in this paper. In conjunction with es-
timates from colleagues, the number of patients treated with the 
enclosed protocol exceeds 1000. To date, of those who followed this 
protocol, we are unaware of a single COVID-19-related death, or of a 
single patient who has required pressure ventilation in an intensive care 
unit. Further, the vast majority of those treated with the regimen have 
exhibited a stereotypic defervescence of symptoms and a marked and 
durable recovery within 4–10 days with only an occasional patient 
reporting features suggestive of “long-hauler’s” syndrome. 
We must replicate our observations in the context of a rigorously 
controlled trial, with methodology aimed to also expose confounding 
influences that always accompany such investigations. Our observations 
from a convenience sample are not, however, irrelevant. This is espe-
cially true given that we base our recommendations upon evidence that 
supports the employment of pragmatic, effective, and timely treatment 
recommendations, just as we would for many other conditions. The 
regimen detailed herein crosses the domains of in-home monitoring, 
application of nutritional principles, pulmonary hygiene, as well as the 
intervention with therapeutic agents aimed at attenuating the inflam-
matory crisis in the lungs while seeking to maintain both ventilation and 
perfusion characteristics, the physiologic coupling of which defines our 
life-sustaining gas exchange apparatus. 
2.1. Application of established medical practice principles 
With the pandemic and its ultrarapid dissemination of infectivity 
throughout the world, our current submission is meant to be a contri-
bution to the cause of reminding clinicians to reach back into the toolbox 
of their general medical training and never forget that there are many such 
tools available to fulfill our first commitment to each and every patient that 
we evaluate. The first commitment is to CARE, and CARE enough to 
employ strategies that were somehow passed over during the ongoing 
pandemic. Quite often, these strategies were opaquely overshadowed by 
the politicization of the world’s medical response to this most unparal-
leled threat to the health and wellness of the human family, and as such, 
of all the nations of the world. 
Having an early treatment protocol for all who test positive, irre-
spective of symptom magnitude, is smart medicine. Why? Symptoms do 
not necessarily reflect the underlying damage happening; a process we 
now know is constitutive, even in those asymptomatic. Why care if you 
don’t have symptoms? The answer is simple; you can change tracks to 
more severe disease and still have morbidity and mortality, and most 
importantly, the damage already sustained may not appear relevant 
now, but may be relevant later, once critical thresholds in tissue damage 
and alveolar loss accumulates. 
2.2. Life sustaining oxygen: supply:demand bioenergetics 
What part of us does NOT need to utilize oxygen? Insufficient oxygen 
delivery compromises mechanisms in our physiology which aim to 
match the supply of energy currency with that of tissue and organ 
functional demands. Most crucially, the amounts of energy currency 
being made (i.e. adenosine triphosphate (ATP)) and its energy currency 
colleagues, flavin adenine dinucleotide (FAD), and nicotinamide adenine 
dinucleotide (NAD), all require oxygen to run the electron transport 
chain in our cellular mitochondria, and may become wholly inadequate 
to maintain the high efficiency state of the health, wellness, and quality 
of life that is inextricably coupled and dependent upon the integrity and 
high fidelity processes which characterize the biochemistry of human 
intermediary metabolism. 
2.3. Consequences of delayed treatment intervention 
If all who are infected are urgently treated, we not only attenuate the 
Prolific Activation of a Network Immune Inflammatory Crisis (‘PANIC’) 
Attack of inflammation, but also abort viral replication [2]. This halt in 
replication abolishes downstream tissue injury mechanisms at both ends 
of the COVID syndrome. These mechanisms include the parochial trig-
gering of ‘PANIC’, where we can least recover from the inflammatory 
crisis, the broncho-alveolar gas exchange units of the most remote rea-
ches of our lung anatomy and physiology. Additionally, the high-jacking 
of our alveolar epithelial molecular machinery for its own self-serving 
purposes causes an additional bystander effect that is the irreversible 
damage and obliteration of this most precious asset of gas exchange, 
which cannot be replaced. 
The prevention, as well as the reversing of the high-jacking of our 
alveolar epithelial cell molecular machinery for purposes of the SARS- 
CoV-2 viral replication, represents another major goal of COVID-19 
treatment. Halting replication itself reduces the inflammatory ignition 
switch that foments site activation of exuberant inflammation, while 
releasing factors (e.g. C3a and C5a; anaphylatoxins and chemotaxins) 
promote the redistribution of peripheral immune effector cells, 
recruiting them to the site of primary infection, the broncho-alveolar 
units. Upon the arrival of the peripheral immune effector cells to the 
primary site of infection, the bronco-alveolar units, the effector cells 
release free radicals, super oxides, and other injurious agents, which all 
serve to intensify and expand the injury cascades. 
Less viral presence also means a reduced likelihood of viral segment 
integration within the alveolar epithelium (as so-called “syncytia”), with 
SPIKE protein ‘dangled’ into the alveolus, potentially generating anti-
body locally from our own B cells. This may sound like a good thing? It is 
not! Such locally generated antibodies against SPIKE protein on the SARS- 
CoV-2 virus expressed upon our alveolar epithelium ignites the terminal 
complement cascade, specifically the C5-convertase. This in turn promotes 
the assembly of proteins derivative of the C5, C6, C7, and C8 pathways 
to construct the terminal and most injurious effector mechanism of the 
entire complement system, the membrane attack complex (MAC). 
In the case of COVID-19, MAC assembly upon our alveolar epithe-
lium is then primed for the final “kill-shot”. Specifically, the MAC ar-
chitecture includes a centrally localized channel which facilitates the 
passage of the terminal complement protein C9 from the opening 
orientation directly toward the alveolar space. The MAC architecture 
serves as a direct line of sight for the bullet-like action of C9 upon 
reaching the terminus of the MAC adhered to the epithelial surface. 
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Upon its arrival, C9 then penetrates the alveolar cell membrane, 
inflicting an irreversible breach in the integrity of the cell’s barrier and 
physiologic dividing line, crucial for maintaining innumerable pro-
cesses, including those that sustain the life and viability of these cells. 
The “kill-shot” mechanism culminates in osmotic shock, completing 
what we now designate as complement-dependent cytotoxicity (CDC). 
What then follows is damage commensurate with the transition to severe 
disease and the heightened risk of alveolar obliteration. 
2.4. Dividends of early/earliest treatment intervention for COVID-19 
Now imagine if all patients were treated at the time of diagnosis, 
when COVID-19 is at its mildest to moderate stages, with interventions 
aimed at multiple mechanisms that when uncoupled, we have our best 
chance to protect the lung, monitor the disease process at home, and 
remain in touch with care providers in order to provide guidance, course 
changes, and always with the default of hospitalization should the 
condition warrant closer observation and/or intensification of the 
treatment plans. 
This is a highly unusual paper. Why? Its principal purpose is to un-
derscore the prospects and possibilities of controlling the most dangerous 
aspects of the COVID-19 pandemic before it begins. Imagine if the world 
recognized that by having the advents of public health practices, 
coupled with an effective out-patient treatment regimen, we could 
prevent hospitalizations and death, while our vaccination programs 
come to fruition and herd immunity is ultimately achieved. 
We absolutely believe this can be achieved if enough of our medical 
community and patient population (essentially everyone) accepts the 
premise of the hypothesis that we put forth. However, we must be 
prepared for new variants, and to learn from the painful and cataclysmic 
lessons of the current pandemic. One glaring observational lesson is that 
the medical community became completely paralyzed by the increasing 
and inevitable onslaught of severe illness, ultimately exceeding our 
available resources. 
One very painful outcome of this past year of the pandemic experi-
ence is that there has been almost a complete lack of management of 
those with mild and moderate disease, as well as those wholly asymp-
tomatic. Unfortunately, it is during this initial time, the initial assess-
ment where patients have been summarily told to ‘go home and not 
return until you are more sick’, that may represent a time when they are 
beyond our capability to nurse them back to health, or even to save their 
lives. 
2.5. Specific aims of our paper and accompanying YouTube video 
This paper is our attempt to focus precisely upon strategies that have 
successfully ‘left-shifted’ patients toward ultimate recovery, and away 
from the potential ‘right-shifting’ to severe disease, and the corre-
sponding escalation in morbidity and mortality associated with it. 
We begin by advancing a number of ‘Imagine’ statements, specif-
ically focused upon the marked mitigation of this pandemic and its ef-
fects upon people, families, communities, and institutions. We then 
detail a specific, albeit not dogmatic, regimen which addresses a di-
versity of semiologic factors associated with COVID-19, and which can 
be remedied with the employment of established practice principles and 
their systematic implementation, given that all that we proscribe, de-
vices, techniques, nutritional agents, and prescription medications, are 
all generic and widely available throughout the world [3–110]. 
This paper is intended to showcase our protocol in conjunction with 
medical illustrations to be utilized for purposes of organization, and for 
counseling each of our individual patients and their families. Similarly, 
we provide a highly detailed figure, along with a table of detailed leg-
ends such that the pathophysiologic underpinnings of COVID-19 can be 
parsed and individually addressed in terms of mitigating or even 
achieving the remission exacting effects of our proposed interventions 
[111–116]. 
This paper is accompanied by a video, published here (click on 
thumbnail) and on YouTube (https://thefrohmanfoundation.org/o 
utpatient-covid-19-treatment-to-prevent-severe-disease/), that shall be 
released in synchrony with the publication of this manuscript. The 
multimedia architecture of the video is intended to inform, educate, 
counsel, inspire, and to build confidence both among those infected, as 
well as their family members, and their CARE provider alliances.    
It is our hope that by bringing this real-world experience to light, it 
shall broadly illuminate for all to see, a systematic strategy capable of 
solving the complex riddle of the SARS-CoV-2 agent, and its clinical 
manifestations as COVID-19. We take a broader view of the inception of 
(Click here)   
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the illness, exploit the vast toolbox of established medical, health, and 
wellness capabilities that can be wielded with predictable effects, 
including the ability to abort the infection, and thereby abolish the 
mechanisms responsible for the consequences of this infection. 
2.6. Preparing for the future: avoid repeating the mistakes from the past 
The reports of new mutations, in conjunction with spikes of the 
illness being disseminated throughout the world, suggest that this paper 
offers a timely plan to mitigate the illness and prevent the transition to 
severe disease. 
This monitoring and treatment protocol recognizes CARE pathways 
addressing each of the early mechanisms and manifestations of this 
illness, while assembling a concerted attack directly upon the culprit, as 
well as applying a treatment strategy which finally is focused upon the 
most relevant constellation of treatable facets of this dangerous, com-
plex, and clever microbial agent [3–116]. 
From the start, we have possessed the tools to ‘checkmate’ this 
challenger, despite it targeting of one of our body’s most vulnerable and 
life-sustaining circuitries. Even at the most remote reaches of our lung 
physiology, employment of site-selective inhalational therapies, in 
conjunction with nutritional support measures, pulmonary hygiene, and 
respiratory muscle training, we can begin to provide a path forward by 
which to prevent symptom worsening and possibly prevent hospitali-
zation, while learning lessons that shall prepare us for future challenges 
that shall no doubt be forthcoming. 
Herein the time is right to now begin by asking you, the reader, to be 
open minded enough to consider the “IMAGINE” statements that follow; 
inspired by John Lennon’s 1971 verse from his raison d’être. 
IMAGINE 
“You may say I’m a dreamer 
But I’m not the only one 
I hope someday you’ll join us 
And the world will be as one” 
John Lennon, October 11, 1971  
Imagine If we could treat patients with COVID-19 at the beginning, when most 
only have mild to moderate disease, thereby preventing severe disease. 
Imagine If the treatment were based on evidenced-based medical principles and 
such a regimen were completely detailed right here for you, your family, 
and your healthcare provider. 
Imagine If, while you are waiting to get vaccinated, those already infected could 
receive a simple treatment regimen along with education on how to 
administer it as an out patient at home, and education on when to contact 
their medical provider or go to the emergency department. 
Imagine If this treatment were cheap, involved both over-the-counter therapies, 
and only a few prescriptions, and was administered over a 10-day course 
in most patients. 
Imagine If the vast majority utilizing such a regimen would never advance to 
severe COVID-19, would NOT require hospitalization, and as such, would 
completely avoid ventilatory support, and death. 
Imagine If the effectiveness of this treatment strategy produced similar protective 
effects across the age, gender, racial, and co-morbid condition 
demographic spectrum. 
Imagine That we know the time to act and initiate treatment is at the time of COVID-19 
diagnosis (pre-emption to avoid progression to severe disease), NOT wait for a 
favorable prognostic outcome that may never materialize, or until the 
patient is sufficiently sick to warrant hospitalization (a reactive and much 
more dangerous strategy). Such delay to act early may be too late to avoid 
progression to severe COVID-19. 
Imagine That we have provided the details of a protocol assembled by our team of 
colleagues, and have already observed nearly uniform capability to rescue 
over 1000 patients at the time when their infection is early in the course. 
A time that represents our best chance to mitigate suffering, and more 
importantly, to prevent progression to severe disease and its associated 
ramifications, including death. 
Imagine Now imagine if the entire world became aware of this early treatment 
regimen, and its ability to prevent progression to severe disease? This is 
NOT unimaginable. Rather, together we can do this; and do this NOW, 
and together we can lives.  
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.jns.2021.117463. 
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Fig. 1. All steps are taken for a total of 10 days. 
[Numbers Correspond to those in Fig. 1] 
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Mucus Clearance & Pulmonary Hygiene
9. Guaifenesin To promote liquification of mucus for subsequent mobilization out of the 
peripheral bronchopulmonary tree, we recommend using guaifenesin
(available over the counter in most countries) twice daily at 1200 mg,
extended-release formulation.
If the cough is excessive or fatiguing, then guaifenesin + dextromethorphan
(the latter, a cough suppressant, can also attenuate adenosine mediated 
headaches) is indicated. 
Thick mucus formation can become organized in the distal bronchioles and 
compromise local and then general ventilation characteristics, ultimately 
affecting gas-exchange at the alveoli apparatus. [38-52]
10.Postural Percussion Mobilization (expectoration) of distal mucus (in those with no cough, non-
productive cough, and with productive cough) by liquefying (following step 9,
above). Follow by either manual postural percussion or use of a percussion
vibratory instrument on the back, to dislodge mucus in the upper and lower 
lobes (right and left), and apply similar percussion to the right middle lobe, also
known as the lingular lobe.
This is key, as the right middle lobe is the one at greatest risk of 
consolidation and infection, along with atelectasis (a partial or complete 
collapse of the lung).
Right middle lobe pulmonary hygiene (i.e. percussion and expectoration) is 
best achieved by having the patient raise their right arm and percuss from 






Performance of pulmonary exercises promotes normalizing pulmonary 
functioning via improved conditioning. 10-20 breaths of inspiration and 
expiration with The Breather (a respiratory muscle trainer which can be purchased 
online, as well as other devices such as incentive spirometry device), three times 
daily. Begin at setting #1; each day see if the patient can advance by one setting 
until arriving at the top setting (e.g. with the highest resistance to inspiration and 
expiration). [56-60]
Fig. 1. (continued). 
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Advance Therapy # 1
13.L-Albuterol & 
Budesonide
We recommend inhalational L-albuterol to facilitate improved ventilation 
and delivery of medication to the distal bronchopulmonary tree. L-albuterol 
has the active “R” isomer of the molecule and serves to relax bronchial smooth 
muscle, and is more lung selective than the racemic form (R & D isomers). 
Albuterol is a beta-2 adrenergic agonist and serves to relax bronchiole smooth 
muscle. Additionally, via its interaction with beta-receptors on lung mononuclear 
cells (especially macrophages, T- and B-lymphocytes), it promotes the escalation 
in intracellular cAMP, and thereby the transition of mononuclear cells from pro-
inflammatory to modulated and even to a regulatory cell phenotype. This 
mitigates the “Prolific Activation of a Network Immune Inflammatory Crisis” 
(PANIC), the principal mechanisms of COVID-19 associated with tissue damage 
of the lungs. [61-65]
We recommend 2 puffs twice daily, along with 2 puffs of a budesonide 
inhaler (Pulmicort) administered 5 minutes after taking L-albuterol inhaler 
therapy, to provide some time for bronchial smooth muscle relaxation.
Administration of L-albuterol improves ventilatory characteristics for the 
site-selective delivery of the inhalational steroid budesonide into the distal 
broncho-alveolar region of the most distal bronchopulmonary tree. This 
subsequently acts to coordinate a constellation of steroid-mediated anti-
inflammatory actions, also serving to mitigate the effects of COVID-19-associated 
inflammatory activity. After administration of the two inhalational puffs of L-
albuterol, followed by the two puffs of budesonide, we recommend that the patient 
gargle with water x 2 and spit, to avoid the development of thrush. [66-67]
14.Baby Aspirin Unless formal anticoagulation is indicated, (per guidelines contingent upon D-
Dimer levels), we recommend 1 baby aspirin daily (81 mg) for purposes of 
reducing clot and sludging via platelet inhibition (unless aspirin in the patient 
is contraindicated). [68-77]
15.Avoid Overhydration Avoid overhydrating because increased protein-rich fluid can accumulate in
the distal bronchopulmonary tree, which can increase the distance between 
the alveolar epithelium and the pulmonary vascular capillary bed endothelium, 
thereby compromising the gas exchange apparatus (as demonstrated in the 
FACCT TRIAL). If your patient is dehydrated (e.g. from diarrhea), then fluid 
reconstitution and potentially potassium repletion may need to be 
considered. [78-82]
16.Proning Lie prone (positioned on your stomach) during sleep (or perhaps 2/3 of 
sleep time prone, the other 1/3 supine).
This improves the oxygen saturation of arterial red blood cell hemoglobin
(as demonstrated in the PROSERVA TRIAL). [83-87]
Fig. 1. (continued). 
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Advance Therapy # 2
Fig. 1. (continued). 
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Fig. 2. Pathophysiology of severe COVID-19 from mild/moderate COVID-19 and the mechanistic treatment for its prevention. 
General Architecture Overall, this figure is dichotomized by characterizing the features of mild 
and moderate COVID-19 and the interventions that comprise our regimen 
to prevent progression to severe disease.
Legend
The color-encased 
boxes are utilized for 
purposes of:
Defining a problem (RED box)
Potential complications from the problem (DOTTED RED box)
Proscribed intervention (GREEN box)




To prevent the organization of complex inspissated mucus with bacterial 
flora in the distal bronchopulmonary tree, potentially serving to “endocast” 
the bronchoalveolar anatomy responsible for ventilation and perfusion 
characteristics germane to high-fidelity gas exchange. 
Mucus Obstruction 
of the distal 
bronchopulmonary 
tree
The SARS-CoV-2 virus, which causes COVID-19, principally does so by 
targeting our most vulnerable lung anatomy, the bronchoalveolar 
terminals where high-fidelity gas exchange occurs, representing the 
entire body’s supply of oxyhemoglobin and its delivery via 
cardiopulmonary physiology [2, 112].
To maintain such constant and uninterrupted gas exchange, both 
ventilation and pulmonary arterial perfusion must be commensurate with 
threshold states that guarantee the reliable delivery of oxygen to the 
pulmonary arterial capillary network, while the lung parenchyma 
simultaneously expels carbon dioxide by reverse expiratory flow,
oscillating with the inspiration of fresh air whose composition is 21% O2. 
Oxygenated pulmonary venous return to the left heart is then prepared to 
deliver cardiac output via the left ventricular systolic pump and its ejection 
fraction of blood in to and out of the aortic root. 
The mobilization of dangerous mucus organization in the distal 
bronchioles is achieved with a combination of: 
1. Liquification via 800-1200mg of oral twice daily guaifenesin, 
2. Excessive cough, which can be counteracted by the use of 
guaifenesin with dextromethorphan
3. Manual percussion of the upper and lower lung lobes from the 
back and anterior percussion of the right middle lobe, which can 
serve to mobilize and ultimately expectorate the mucus burden in 
the distal lung fields. 
4. Percussion and mucus expectoration, which is more efficiently 
achieved by utilizing a vibratory “gun,” making this part of 
pulmonary hygiene less cumbersome and exhausting for the 
assistant, partner, or family member. 
5. Special attention given to the right middle lung lobe, approaching 
anteriorly (between the 4th-6th intercostal spaces, with the breast 
lifted in those with abundant breast tissue) Remember that the 
right middle lobe is most predisposed to the development of 
pneumonic consolidation (i.e. pneumonia and pneumonitis), as 
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This “Necessary Drug”, as designated by the World Health Organization 
(WHO), exerts broad pleiotropic mechanisms. These mechanisms 
include:  
 
 pharmacologic duality as both a folate analog, as well as folate 
antagonist,  
 cell cycle S-phase inhibitor,  
 inhibition of DNA and RNA base synthesis for both purines and 
pyrimidines, thereby exerting a powerful inhibition of viral 
replication (including that of SARS-CoV-2)  
 marked attenuation of cytokine release syndromes,  
 modulation of adenosine mediated anti-inflammatory 
mechanisms,  
 inhibition of NFB, and  
 promotion of the production of tissue inhibitors of 
metalloproteinases [TIMPS], modulation of JAK/STAT signaling 
platforms, modulation of reactive oxygen species, and inhibition 
of the binding of HMGB1 to RAGE, or indirectly interfering with 
this interaction via inhibition of the cytokine production of TNF-, 










There does come a time when the above interventions are not sufficient 
to avoid the “right-shifting” of the patient from mild/moderate COVID-19 
into severe disease. Such circumstances necessitate hospital admission 
for: 
1. Close observation 
2. Augmentation of oxygen support (e.g. 1-4 L of O2 by nasal 
cannula 
3. Expanded investigations to ascertain the severity of metabolic 
and hematologic derangements (Ferritin, hsCRP, D-Dimer), 
presence of concomitant infection (including secondary 
pneumonia, if bacterial suspected prompting treatment with IV 
antibiotics), and CT assessment of the lung, to stage the severity 
and burden of injury to the lung parenchyma. Further, cardiac 
investigations are increasingly being performed given increasing 
evidence that COVID-19 can affect the heart, predisposing 
patients to markedly increased morbidity and mortality.  
To diagnostically and therapeutically address extra-pulmonary 
organ pathologies, such as brain imaging to assess for stroke, 
renal insufficiency or failure, and endocrine and neuroendocrine 
pathology.  
4. Multidisciplinary management  
5. Intensive care unit (ICU) management 
6. Consideration of intensive interventions (e.g. plasma, high dose 
IV methotrexate with leucovorin rescue; monoclonal antibodies 
against IL-1, IL-6, etc) 
7. Ventilator support  
Fig. 2. (continued). 
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